Will Cochrane retract their Review of Exercise Therapy for ME/CFS or publish an updated review (against GET) by 2029?
Health & MedicineOne-Off2a
Manifold MarketsSans KYCDonnées de résolution vérifiéesAssez bien calibréPrévision communautaire actuelle
Oui 79.5%
Prévisionnistes
5
Type de question
binary
Méthodologie
Play-money forecasting platform
Type de source
Prévision
Données du marché
Mis à jour il y a 18 heures
Obsolète30 juin 24, 16:24 UTC31 déc. 28, 22:59 UTC
Tendances
Marchés Associés
Questions liées pour le contexte, et non une comparaison de contrats équivalents.
Will ME/CFS blood test replicate in larger study?
Manifold MarketsWill the finding of high WASF3 in ME/CFS (Hwang,PNAS, 2023) be successfully replicated by the end of 2027?
Manifold MarketsCommercially available tooth regeneration therapy
Manifold MarketsHantavirus pandemic in 2026?
PolymarketWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
KalshiFDA approves skin cancer vaccine by which date?
PolymarketRègles
In 2019 Cochrane published a review concluding graded exercise therapy (GET) was beneficial for people with ME/CFS.
- This goes against nearly every other major organisation, whom say that exercise therapy is harmful for people with ME/CFS:
- CDC (Since 2017) (US)
- NICE and NHS (since 2021) (UK)
- Mayo Clinic (Since 2024) (US)
- Australian ME/CFS Guidelines (Since 2024) (Australia)
Marchés ouverts
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.2pt97%
- Yes+0.2pt3%
- Volume total
- 15,6 M €
- Volume 24h
- 20,3 k €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+0.6pt4%
- Volume total
- 1,6 M €
- Volume 24h
- 8 k €
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+4.0pt65%
- September41%
- June28%
- Volume total
- 84,1 k €
POLYMARKETEbola pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Volume total
- 652,6 k €
- Volume 24h
- 3,4 k €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-4.0pt58%
+2 résultats de plus
- Volume total
- 865,4 k €
- Volume 24h
- 3 k €
POLYMARKETNew pandemic in 2026?
- No+1.0pt94.1%
- Yes-1.0pt5.9%
- Volume total
- 915,2 k €
- Volume 24h
- 1,2 k €
- When will the FDA approve Intellia Therapeutics' lonvo-z?
- Will 3 mg THC beverages be federally legal to sell?
- Measles cases in U.S. in 2026?
- Cyclosporiasis cases reported in the US in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve CagriSema?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
Questions fréquentes
- Quelles sont les probabilités actuelles pour Will Cochrane retract their Review of Exercise Therapy for ME/CFS or publish an updated review (against GET) by 2029? ?
- Manifold Markets cote Yes à 80% au 8 septembre 2026.
- Quand Will Cochrane retract their Review of Exercise Therapy for ME/CFS or publish an updated review (against GET) by 2029? sera-t-il résolu ?
- Will Cochrane retract their Review of Exercise Therapy for ME/CFS or publish an updated review (against GET) by 2029? doit être résolu le 31 décembre 2028.
- Comment Will Cochrane retract their Review of Exercise Therapy for ME/CFS or publish an updated review (against GET) by 2029? est-il réglé ?
- Manifold Markets règle ce marché comme suit : In 2019 Cochrane published a review concluding graded exercise therapy (GET) was beneficial for people with ME/CFS.